BFC
CTIC

Bedel Financial Consulting’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Bedel Financial Consulting’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed – – 1008
2022
Q1 		$0 Hold
10
– – ﹤0.01% 1111
2021
Q4 		$0 Hold
10
– – ﹤0.01% 1120
2021
Q3 		$0 Hold
10
– – ﹤0.01% 1060
2021
Q2 		$0 Buy
+10
New +$24 ﹤0.01% 1044

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bedel Financial Consulting's CTIC Position: Q2 2022 in Review

Bedel Financial Consulting sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2022, closing a stake of 10 shares.

Bedel Financial Consulting first reported a position in CTIC in Q2 2021 and held it in 4 quarters. The position peaked at $0 in Q1 2022. 119 funds tracked by Wall St. Rank hold CTIC as of Q2 2022.

  • Bedel Financial Consulting reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 10 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2022.
  • Bedel Financial Consulting first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q1 2022.
  • 119 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.